Literature DB >> 23278588

Neuromuscular transmission failure in myasthenia gravis: decrement of safety factor and susceptibility of extraocular muscles.

Alessandro Serra1, Robert L Ruff, Richard John Leigh.   

Abstract

An appropriate density of acetylcholine receptors (AChRs) and Na(+) channels (NaChs) in the normal neuromuscular junction (NMJ) determines the magnitude of safety factor (SF) that guarantees fidelity of neuromuscular transmission. In myasthenia gravis (MG), an overall simplification of the postsynaptic folding secondary to NMJ destruction results in AChRs and NaChs depletion. Loss of AChRs and NaChs accounts, respectively, for 59% and 40% reduction of the SF at the endplate, which manifests as neuromuscular transmission failure. The extraocular muscles (EOM) have physiologically less developed postsynaptic folding, hence a lower baseline SF, which predisposes them to dysfunction in MG and development of fatigue during "high performance" eye movements, such as saccades. However, saccades in MG show stereotyped, conjugate initial components, similar to normal, which might reflect preserved neuromuscular transmission fidelity at the NMJ of the fast, pale global fibers, which have better developed postsynaptic folding than other extraocular fibers.
© 2012 New York Academy of Sciences.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 23278588      PMCID: PMC3539765          DOI: 10.1111/j.1749-6632.2012.06841.x

Source DB:  PubMed          Journal:  Ann N Y Acad Sci        ISSN: 0077-8923            Impact factor:   5.691


  26 in total

1.  Rapid eye movements in myasthenia gravis. I. Clinical observations.

Authors:  D G Cogan; R D Yee; J Gittinger
Journal:  Arch Ophthalmol       Date:  1976-07

2.  Neuromuscular junction in myasthenia gravis: decreased acetylcholine receptors.

Authors:  D M Fambrough; D B Drachman; S Satyamurti
Journal:  Science       Date:  1973-10-19       Impact factor: 47.728

3.  Division of labor in human extraocular muscle.

Authors:  A B Scott; C C Collins
Journal:  Arch Ophthalmol       Date:  1973-10

4.  Myasthenia gravis induced by monoclonal antibodies to acetylcholine receptors.

Authors:  V A Lennon; E H Lambert
Journal:  Nature       Date:  1980-05-22       Impact factor: 49.962

5.  Inflammation at the neuromuscular junction in myasthenia gravis.

Authors:  R A Maselli; D P Richman; R L Wollmann
Journal:  Neurology       Date:  1991-09       Impact factor: 9.910

6.  Histometric analysis of the ultrastructure of the neuromuscular junction in myasthenia gravis and in the myasthenic syndrome.

Authors:  A G Engel; T Santa
Journal:  Ann N Y Acad Sci       Date:  1971-09-15       Impact factor: 5.691

7.  Myasthenic immunoglobulin accelerates acetylcholine receptor degradation.

Authors:  I Kao; D B Drachman
Journal:  Science       Date:  1977-04-29       Impact factor: 47.728

8.  Ultrastructural localization of the acetylcholine receptor in myasthenia gravis and in its experimental autoimmune model.

Authors:  A G Engel; J M Lindstrom; E H Lambert; V A Lennon
Journal:  Neurology       Date:  1977-04       Impact factor: 9.910

9.  Pathological mechanisms in experimental autoimmune myasthenia gravis. I. Immunogenicity of syngeneic muscle acetylcholine receptor and quantitative extraction of receptor and antibody-receptor complexes from muscles of rats with experimental automimmune myasthenia gravis.

Authors:  J M Lindstrom; B L Einarson; V A Lennon; M E Seybold
Journal:  J Exp Med       Date:  1976-09-01       Impact factor: 14.307

10.  Pathological mechanisms in experimental autoimmune myasthenia gravis. II. Passive transfer of experimental autoimmune myasthenia gravis in rats with anti-acetylcholine recepotr antibodies.

Authors:  J M Lindstrom; A G Engel; M E Seybold; V A Lennon; E H Lambert
Journal:  J Exp Med       Date:  1976-09-01       Impact factor: 14.307

View more
  16 in total

1.  Collagen XIII Is Required for Neuromuscular Synapse Regeneration and Functional Recovery after Peripheral Nerve Injury.

Authors:  Zarin Zainul; Anne Heikkinen; Hennariikka Koivisto; Iina Rautalahti; Mika Kallio; Shuo Lin; Heli Härönen; Oula Norman; Markus A Rüegg; Heikki Tanila; Taina Pihlajaniemi
Journal:  J Neurosci       Date:  2018-04-06       Impact factor: 6.167

2.  Terminal Schwann cells participate in neuromuscular synapse remodeling during reinnervation following nerve injury.

Authors:  Hyuno Kang; Le Tian; Michelle Mikesh; Jeff W Lichtman; Wesley J Thompson
Journal:  J Neurosci       Date:  2014-04-30       Impact factor: 6.167

Review 3.  Post-synaptic specialization of the neuromuscular junction: junctional folds formation, function, and disorders.

Authors:  Suqi Zou; Bing-Xing Pan
Journal:  Cell Biosci       Date:  2022-06-19       Impact factor: 9.584

4.  Cigarette Smoking and Activities of Daily Living in Ocular Myasthenia Gravis.

Authors:  Sean M Gratton; Angela M Herro; William J Feuer; Byron L Lam
Journal:  J Neuroophthalmol       Date:  2016-03       Impact factor: 3.042

5.  Ocular myasthenia gravis: controversies and updates.

Authors:  Sui H Wong; Saif Huda; Angela Vincent; Gordon T Plant
Journal:  Curr Neurol Neurosci Rep       Date:  2014-01       Impact factor: 5.081

6.  Altered active zones, vesicle pools, nerve terminal conductivity, and morphology during experimental MuSK myasthenia gravis.

Authors:  Vishwendra Patel; Anne Oh; Antanina Voit; Lester G Sultatos; Gopal J Babu; Brenda A Wilson; Mengfei Ho; Joseph J McArdle
Journal:  PLoS One       Date:  2014-12-01       Impact factor: 3.240

Review 7.  Rapid and reversible responses to IVIG in autoimmune neuromuscular diseases suggest mechanisms of action involving competition with functionally important autoantibodies.

Authors:  Melvin Berger; Daniel E McCallus; Cindy Shin-Yi Lin
Journal:  J Peripher Nerv Syst       Date:  2013-12       Impact factor: 3.494

8.  The Rac-GAP alpha2-Chimaerin Signals via CRMP2 and Stathmins in the Development of the Ocular Motor System.

Authors:  Luis Carretero-Rodriguez; Ragnheiður Guðjónsdóttir; Ivana Poparic; Madeline Louise Reilly; Mary Chol; Isaac H Bianco; Marco Chiapello; Renata Feret; Michael J Deery; Sarah Guthrie
Journal:  J Neurosci       Date:  2021-06-24       Impact factor: 6.167

9.  An adult patient with ocular myasthenia and unusually long spontaneous remission.

Authors:  Jasem Al-Hashel; Hanaa M Rashad; Rossen T Rousseff
Journal:  Case Rep Neurol Med       Date:  2014-04-13

10.  Keep an eye out for myasthenia gravis patients with an eye out.

Authors:  A Arturo Leis; Alan R Moore
Journal:  Front Neurol       Date:  2014-07-01       Impact factor: 4.003

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.